快猫短视频

Skip to main content
showDesktop,showTablet,showMobile

Tumor Treating Fields (TTF) Therapy for Mesothelioma

Researchers have found that exposing some types of cancer cells to alternating electric fields, also known as tumor treating fields (or TTFields), can interfere with the cells’ ability to grow and spread.

A wearable device known as Optune Lua is a TTFields treatment that creates such electric fields. It is an option to help treat some people with mesothelioma.

When might TTFields be used to treat mesothelioma?

Optune Lua can be used along with chemotherapy to treat some people with advanced pleural mesothelioma that can't be removed with surgery.

How is TTFields therapy given?

For this treatment, the chest and/or back is shaved (if needed), and pads containing sets of electrodes are placed on the skin, usually 2 on the chest and 2 on the back.

The electrodes are attached to a battery pack (kept in a backpack) and are worn for most of the day - typically at least 18 hours. They create mild electric currents that are thought to affect cancer cells more than normal cells.

Possible side effects of TTFields therapy

Side effects of the device are usually limited to the electrode sites. They can include:

  • Skin irritation
  • Allergic reactions
  • L?ocal warmth and tingling sensations
  • M?uscle twitching
  • Infections
  • Breakdown of the skin (ulcers)

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

Tsao AS. Systemic treatment for unresectable malignant pleural mesothelioma. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma on October 28, 2024.

Last Revised: October 28, 2024

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.